ClinicalTrials.gov Postings Should Include Studies For All Diseases – PhRMA
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA revises earlier policy, which advised companies to post trials only for “serious and life-threatening” conditions, as mandated by FDAMA. Policy change comes as international trade associations adopt universal principles on clinical trial disclosure.